The U.S. FDA has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab).

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

Treatment with TNF inhibitors may be beneficial over phototherapy in reducing the risk for psoriatic arthritis in patients ...

J&J said it had a “biosimilar readiness plan” to thwart Pfizer's attempt to steal sales from Remicade with its cheaper biosimilar.

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

Which of the statements about the use of tumor necrosis factor inhibitors for managing rheumatic disorders are correct?